U
OSIR

UBS’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

UBS’s Portfolio OSIR Stock Details OSIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$123K Buy
9,799
+8,199
+512% +$117K ﹤0.01% 5755
2014
Q2 		$25K Sell
1,600
-3,362
-68% -$49.4K ﹤0.01% 7825
2014
Q1 		$65K Sell
4,962
-759
-13% -$11.9K ﹤0.01% 6516
2013
Q4 		$92K Sell
5,721
-11,830
-67% -$189K ﹤0.01% 6170
2013
Q3 		$292K Buy
17,551
+11,615
+196% +$172K ﹤0.01% 4734
2013
Q2 		$60K Buy
+5,936
New +$62.4K ﹤0.01% 6522

Other funds holding OSIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

UBS's OSIR Position: Q3 2014 in Review

UBS increased its Osiris Therapeutics, Inc. Common Stock (OSIR) stake by 512% in Q3 2014, buying an estimated $117K and bringing the position to 9,799 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #5755.

UBS first reported a position in OSIR in Q2 2013 and has held it in 6 quarters since. The position peaked at $292K in Q3 2013. 67 funds tracked by Wall St. Rank hold OSIR as of Q3 2014.

  • UBS held 9,799 shares of Osiris Therapeutics, Inc. Common Stock worth $123K as of Q3 2014.
  • UBS bought 8,199 Osiris Therapeutics, Inc. Common Stock shares in Q3 2014, an estimated $117K.
  • Osiris Therapeutics, Inc. Common Stock made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5755 holding.
  • UBS first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and has held it in 6 quarters since.
  • UBS's Osiris Therapeutics, Inc. Common Stock position peaked at $292K in Q3 2013.
  • 67 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.